Bristol-Myers Squibb Co. (BMY)

Quick facts

Marketed products

• Eliquis · Cardiovascular · revenue 14443
  Apixaban selectively inhibits Factor Xa, decreasing thrombin generation and thrombus development.
• Opdivo · Oncology · revenue 9200
  Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells.
• Revlimid · Oncology · revenue 5809
  Lenalidomide targets cereblon to degrade substrate proteins, inducing cytotoxicity and immunomodulation.
• Orencia · Immunology · revenue 3705
  Abatacept inhibits T-cell activation by binding CD80/CD86, blocking CD28 costimulatory interaction.
• Pomalyst · Oncology · revenue 2800
  Pomalyst works by binding to the cereblon protein, which disrupts the function of certain genes involved in cancer cell growth.
• Breyanzi · Oncology · revenue 1358
• Zeposia · Immunology · revenue 800
  Zeposia works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression.
• Camzyos · Cardiovascular · revenue 600
  Mavacamten selectively inhibits cardiac myosin, reducing force-producing cross-bridge formation and improving cardiac function in HCM.
• Abecma · Oncology · revenue 427
• Sotyktu · Immunology · revenue 291
  Sotyktu works by blocking the TYK2 enzyme, which is involved in the inflammatory response and contributes to the development of psoriasis.
• Krazati · Oncology · revenue 205
  Krazati works by binding to and inhibiting the GTPase activity of the KRAS G12C protein, preventing it from sending signals that promote cancer cell growth.
• abatacept (ABA) · Immunology
  Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.
• Acetadote · Metabolic
  Acetylcysteine reduces liver injury from acetaminophen overdose by maintaining glutathione levels or providing alternate conjugation substrate.
• Adefovir/Entecavir · Virology/Infectious Disease
  Adefovir and entecavir are nucleoside/nucleotide reverse transcriptase inhibitors that block hepatitis B virus (HBV) replication by inhibiting viral polymerase.
• Advanced therapy
• Arikayce Kit · Immunology
  Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria.
• REZIPAS · Infectious Disease
• Unasyn · Immunology
• Reyataz · Immunology
  Reyataz works by blocking the protease enzyme, which is essential for the replication of HIV.
• Atazanavir + 2 NRTIs · Infectious Disease / Virology
  Atazanavir inhibits HIV protease to prevent viral replication, combined with two nucleoside reverse transcriptase inhibitors (NRTIs) that block reverse transcription of viral RNA.
• Atazanavir + Ritonavir + 2 NRTIs · Infectious Disease / Virology
  Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts atazanavir levels, and the two NRTIs inhibit reverse transcriptase to block HIV DNA synthesis.
• Atazanavir/Ritonavir + Famotidine · Infectious Disease / Virology
  Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts atazanavir levels, and famotidine reduces gastric acid to improve atazanavir absorption.
• Atazanavir-Ritonavir/ Stavidine / Lamivudine · Infectious Disease / Virology
  This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps in the HIV life cycle.
• Atazanavir/ Stavidine / Lamivudine · Infectious Disease / Virology
  This combination inhibits HIV replication by blocking reverse transcriptase and protease enzymes required for viral reproduction.
• Vidaza · Oncology
  Vidaza works by incorporating itself into DNA and interfering with the enzyme that adds methyl groups, which helps to restore normal gene function in cancer cells.
• Azactam · Infectious Disease
  Aztreonam inhibits bacterial cell wall synthesis, acting as a bactericidal agent.
• Baraclude · Infectious Disease
• BECLABUVIR · Infectious Disease
• Nulojix · Immunology
  Nulojix blocks the activation of T cells by binding to CD80, preventing an immune response.
• Blenoxane · Oncology
  Bleomycin works by binding to DNA and causing strand breaks, which ultimately leads to cell death.
• BMS-986165 · Immunology
  BMS-986165 is a selective inhibitor of the interleukin-12 and interleukin-23 (IL-12/IL-23) p40 subunit that reduces inflammatory signaling in immune-mediated diseases.
• BMS-986374 · Oncology
  BMS-986374 is a selective inhibitor of protein arginine methyltransferase 5 (PRMT5) that blocks symmetric dimethylarginine formation on target proteins.
• Cefaprin · Metabolic
• Cefradex · Immunology
• Cocktail · Other
• Daklinza · Oncology
• Videx · Immunology
• Sustiva · Immunology
  Sustiva works by binding to the reverse transcriptase enzyme, preventing the replication of viral RNA.
• efavirenz, stavudine extended release, lamivudine
• Huluc63 · Oncology
  Huluc63 works by binding to the SLAMF7 protein on the surface of cancer cells, stimulating the immune system to attack and kill the cells.

Phase 3 pipeline

• ABA, open-label (OL) · Oncology
  Nivolumab is an immune checkpoint inhibitor that blocks the PD-1 receptor, allowing the immune system to attack cancer cells.
• Abatacept subcutaneous · Immunology
  Abatacept is a fusion protein that blocks T-cell co-stimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.
• Adefovir (ADV) · Virology / Infectious Disease
  Adefovir is a nucleotide reverse transcriptase inhibitor that blocks viral DNA polymerase, preventing replication of hepatitis B virus.
• Antidepressant + Aripiprazole · Psychiatry/Mental Health
  This combination enhances serotonergic and noradrenergic neurotransmission via antidepressant action while aripiprazole provides dopaminergic stabilization and augmentation of antidepressant efficacy.
• Asunaprevir (ASV) · Virology / Hepatology
  Asunaprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication by preventing the cleavage of viral polyproteins.
• Atazanavir capsules · Infectious Disease
  Atazanavir inhibits HIV protease, preventing the cleavage of viral polyproteins and blocking the maturation of infectious HIV particles.
• Atazanavir (immediate switch) · Infectious Disease
  Atazanavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and inhibiting viral replication.
• Atazanavir + ritonavir + tenofovir + nucleoside · Infectious Disease / Virology
  This combination inhibits HIV protease and reverse transcriptase to suppress viral replication in HIV-infected patients.
• Atazanavir + saquinavir + tenofovir + nucleoside · Infectious Disease / Virology
  This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.
• Atazanavir (Week 24 switch) · Infectious Disease
  Atazanavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and stopping HIV replication.
• Atazanvir/ritonavir + efavirenz · Infectious Disease
  This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.
• Belatacept LI (less intensive) · Immunology
  Belatacept is a selective T-cell costimulation blocker that inhibits T-cell activation by binding to CD80/CD86 on antigen-presenting cells.
• Belatacept MI (more intensive) · Immunology
  Belatacept is a selective T-cell costimulation blocker that inhibits CD80/CD86 binding to CD28, preventing T-cell activation and proliferation.
• BMS-650032 (Asunaprevir) · Virology / Hepatology
  Asunaprevir is a hepatitis C virus (HCV) NS3 protease inhibitor that blocks viral protein processing and replication.
• BMS-790052 (Daclatasvir) · Virology/Infectious Disease
  Daclatasvir inhibits the hepatitis C virus NS5A protein, blocking viral replication and spread.
• BMS-936558 (Nivolumab) · Oncology
  Nivolumab blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells.
• BMS-986205 · Immunology
  BMS-986205 is a selective inhibitor of the NLRP3 inflammasome that reduces excessive inflammatory responses by blocking a key protein complex involved in innate immunity.
• BMS-986278 · Immunology
  BMS-986278 is a selective inhibitor of the NLRP3 inflammasome that reduces excessive inflammatory responses by blocking a key protein complex involved in innate immunity.
• Carboplatin/Paraplatin · Oncology
  Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cancer cell replication and inducing cell death.
• Cetuximab/Erbitux · Oncology
  Cetuximab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing tumor growth and survival signals.
• Cisplatin/Platinol · Oncology
  Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and triggering cancer cell death.
• DCV · Virology / Hepatology
  DCV is a direct-acting antiviral agent that inhibits the hepatitis C virus NS5B RNA-dependent RNA polymerase, blocking viral replication.
• DCV 3DAA · Virology / Hepatology
  DCV 3DAA is a fixed-dose combination of three direct-acting antivirals that inhibit hepatitis C virus NS3/4A protease, NS5B polymerase, and NS5A protein to block viral replication.
• DCV/ASV/BMS-791325 · Virology / Hepatology
  This is a three-drug combination of direct-acting antivirals (DCV, ASV, and BMS-791325) that inhibit hepatitis C virus NS5A, NS3 protease, and NS5B polymerase respectively to block viral replication.
• Double-blind Abatacept · Immunology
  Abatacept is a fusion protein that blocks T-cell co-stimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.
• Fluorouracil/Adrucil · Oncology
  Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cancer cell death.
• HCTZ monotherapy · Cardiovascular
  HCTZ (hydrochlorothiazide) is a thiazide diuretic that reduces blood pressure by inhibiting sodium and chloride reabsorption in the distal convoluted tubule of the kidney.
• Infliximab (INF) + MTX, DB · Immunology
  Infliximab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha signaling, while methotrexate (MTX) is a disease-modifying antirheumatic drug (DMARD) that inhibits folate metabolism and immune cell proliferation.
• Intravenous (IV) abatacept · Immunology
  Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.
• Irbesartan/HCTZ · Cardiovascular
  Irbesartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide acts as a thiazide diuretic to reduce fluid volume.
• Irbesartan monotherapy · Cardiovascular
  Irbesartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.
• KarX-EC
  KarX-EC is an extended-release formulation designed to improve the pharmacokinetic profile and therapeutic delivery of its active component.
• Lopinavir/ritonavir + tenofovir + nucleoside · Infectious Disease / Virology
  This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps in the HIV life cycle.
• LPV · Infectious Disease
  LPV is a protease inhibitor that blocks HIV protease, preventing the maturation of HIV virions and reducing viral replication.
• Nivolumab and rHuPH20 · Oncology
  Nivolumab blocks PD-1 on immune cells to restore anti-tumor immunity, while rHuPH20 (recombinant human hyaluronidase) enhances drug penetration into tumors by degrading the hyaluronic acid-rich extracellular matrix.
• Nivolumab-relatlimab FDC · Oncology
  This fixed-dose combination blocks both PD-1 and LAG-3 checkpoints on immune cells, releasing dual brakes on anti-tumor immunity.
• Nivolumab/rHuPH20 · Oncology
  Nivolumab is a PD-1 inhibitor that blocks immune checkpoint signaling, while rHuPH20 is a recombinant human hyaluronidase that enhances subcutaneous drug delivery and bioavailability.
• NKTR-214 · Oncology
  NKTR-214 is an engineered interleukin-2 (IL-2) cytokine that preferentially activates and expands CD8+ T cells and NK cells to enhance anti-tumor immune responses.
• Open-label Abatacept · Immunology
  Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.
• PLA + MTX switched to ABA+ MTX, DB · Immunology
  Abatacept (ABA) is a T-cell costimulation inhibitor that blocks the interaction between antigen-presenting cells and T cells, reducing inflammatory immune responses when combined with methotrexate (MTX).

Phase 2 pipeline

• Anti-IL8 · Immunology
  Anti-IL8 binds to interleukin-8 (IL-8), a chemokine involved in inflammation, to reduce its activity.
• Anti-IP-10 Antibody · Immunology
  Anti-IP-10 Antibody works by binding to IP-10, a chemokine involved in the recruitment of immune cells to sites of inflammation.
• Any biologic treatment for psoriasis · Immunology
  Tildrakizumab blocks the interaction between interleukin-23 (IL-23) and its receptor, reducing inflammation in the body.
• Approved Hypertrophic Cardiomyopathy drug treatments · Cardiovascular
  Calcium channel blocker
• Aurexis® · Psychiatry
  Selective serotonin reuptake inhibitor
• BET Inhibitor · Oncology
  BET inhibitor targets bromodomain and extra-terminal domain (BET) proteins
• BMS-562086
• BMS-650032 · Oncology
  BMS-650032 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance anti-tumor immune response.
• BMS-708163 · Neurology
  BMS-708163 inhibits the activity of beta-secretase (BACE1), an enzyme involved in the production of amyloid-beta peptides, which are associated with Alzheimer's disease.
• BMS-790052 · Oncology
  BMS-790052 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance anti-tumor immune responses.
• BMS-914392
• BMS-954561 · Oncology
  BMS-954561 is a small molecule that targets the CD47/SIRPα axis.
• BMS-986012
• BMS-986016
• BMS-986165 Dose A · Oncology
  BMS-986165 Dose A is an anti-PD-1 monoclonal antibody.
• BMS-986165 Dose B · Oncology
  BMS-986165 is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, thereby enhancing the immune response against cancer cells.
• BMS-986166
• BMS-986177 · Oncology
  BMS-986177 is an anti-PD-1 monoclonal antibody.
• BMS-986207
• BMS-986213
• BMS-986231 · Oncology
  BMS-986231 is an anti-PD-1 monoclonal antibody.
• BMS-986259
• BMS-986322
• BMS-986340
• BMS-986435
• BMS-986446
• BMS-986504 · Oncology
  BMS-986504 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance immune response against cancer cells.
• CCR2 Antagonist
• Corticosteroid: Dexamethasone
• Corticosteroid: Fludrocortisone
• Corticosteroid: Hydrocortisone
• Corticosteroid: Meprednisone · Oncology
  Glucocorticoid receptor agonist
• Corticosteroid: Methylprednisolone · Oncology
  Glucocorticoid receptor agonist
• Corticosteroid: Prednisone · Immunology
  Glucocorticoid receptor agonist
• Corticosteroid: Triamcinolone · Oncology
  Glucocorticoid receptor agonist
• CXL-1427
• Erythropoiesis-stimulating agents
• HNO Donor
• HuMax-IL8
• IMiD treatment

Phase 1 pipeline

• [11C]BMT-136088
• [13C]-BMS-791325
• [14C] BMS-813160
• [14C] BMS-986020
• [14C]BMS-986177 Solution for Infusion
• [14C]-BMS-986196
• [14C] BMS-986278
• [14C]BMS-986419

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Bristol-Myers Squibb Co. portfolio CI brief
• Bristol-Myers Squibb Co. pipeline updates RSS